Sign In
Buy IBB
$167.50
+3.23 (+1.97%)
At Close: Jun 03, 2026
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
10:30am, Friday, 11'th Apr 2025
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told
Explainer: Prescription drugs become a target in Trump's trade war
02:27pm, Wednesday, 09'th Apr 2025
U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm t
Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'
01:06pm, Wednesday, 09'th Apr 2025
Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.
Why drug stocks are no longer a safe haven from the stock market's turmoil
11:49am, Wednesday, 09'th Apr 2025
Shares of drugmakers were taking a broad beating Wednesday, after President Donald Trump indicated that pharmaceuticals will no longer be excluded from tariffs.
Should You Invest in the iShares Biotechnology ETF (IBB)?
07:20am, Monday, 07'th Apr 2025
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund launched on 02/05
Invest In A New Biotech Bull Market With XBI And IBB
08:33am, Sunday, 02'nd Mar 2025
Biotech stocks are oversold. This near-term bottom might be the start of a long-term bull run. IBB and XBI offer different advantages. IBB can benefit from the flight to safety trade. XBI provides mor
Seeking Stocks With Vitality In The Volatile Healthcare Sector
11:06am, Tuesday, 25'th Feb 2025
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US admini
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
07:21am, Tuesday, 11'th Feb 2025
The iShares Biotechnology ETF (IBB) made its debut on 02/05/2001, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.
Stock Market Rotation: To Healthcare (XLV), Then Biotechnology (IBB)
10:10am, Thursday, 06'th Feb 2025
Here are some of the recent references I have made about Biotechnology Sector (IBB) and the potential for a rally. Incidentally, Moderna (MRNA) is so oversold on a monthly timeframe, it should be on y
How tariffs could impact pharma and early-stage healthcare investments
06:43pm, Monday, 03'rd Feb 2025
Carl Rizzuto, Versant Ventures managing director, joins 'Fast Money' to talk the impact of tariffs on healthcare.
Can Health Care ETFs Aid Your Portfolio?
07:49am, Monday, 03'rd Feb 2025
The Health Care Select Sector SPDR ETF (XLV) was up approximately 6% year-to-date as of January 29. While it is still early days, this performance is already twice as robust as the sector ETF's perfor
Should You Invest in the iShares Biotechnology ETF (IBB)?
07:26am, Monday, 03'rd Feb 2025
Launched on 02/05/2001, the iShares Biotechnology ETF (IBB) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.
Biotech walks a 'tightrope' amid unclear funding, regulations
07:06pm, Thursday, 30'th Jan 2025
Earlier this week, the Trump administration froze and then rescinded the freeze on federal funding for several programs, including research funding that the biotech industry relies on. Clear Street se
I Was Convinced Biotech Stocks Were Too Risky—This Innovation's Changing the Game
12:01pm, Thursday, 23'rd Jan 2025
The biotech scene can be seen as fairly risky for new investors who want to put money to work.
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
06:10pm, Monday, 13'th Jan 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil
